立体定向消融放疗治疗寡进展转移性肾癌的II期试验
这项单臂II期试验在20例接受一线至四线系统治疗、进展部位≤3处且累及≤30%全部病灶的转移性肾细胞癌患者中,评估立体定向消融放疗(SAbR)能否将ongoing系统治疗延长超过6个月。结果显示14例(70%,95%CI 49.9-90.1)患者系统治疗延长超过6个月,局部控制率100%,1例出现可能与治疗相关的3级胃肠道毒性,生活质量无显著下降。作者认为数据支持在前瞻性随机临床试验中评估SAbR用于寡进展mRCC。
要点
- 20例寡进展mRCC患者接受SAbR,14例(70%)ongoing系统治疗延长超过6个月。
- 局部控制率100%,中位至新系统治疗或死亡时间11.1个月(95%CI 4.5-19.3)。
- 1例发生可能与治疗相关的3级胃肠道毒性,生活质量无显著下降。
核心结论
- SAbR延长了寡进展mRCC患者ongoing系统治疗的持续时间,且未损害生活质量。
- 这些数据支持在前瞻性随机临床试验中评估SAbR用于寡进展mRCC。
研究设计与样本
- 单臂II期临床试验,在大学医学中心和县医院开展,纳入20例接受一线至四线系统治疗的mRCC患者。
- 入组条件为进展部位(包括新发部位)≤3处且累及≤30%全部病灶。
主要发现
- 共对37个部位实施初始及纵向SAbR,局部控制率为100%。
- 中位随访10.4个月(四分位距5.8-16.4),14例(70%,95%CI 49.9-90.1)患者ongoing系统治疗延长超过6个月。
- 从SAbR至开始新系统治疗或死亡的中位时间为11.1个月(95%CI 4.5-19.3)。
- SAbR辅助下的系统治疗中位持续时间为24.4个月(95%CI 15.3-42.2)。
- 中位总生存未达到;1例发生可能与治疗相关的3级胃肠道毒性;生活质量无显著下降。
局限性
- 局限性包括非随机设计和小样本队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapy sometimes progress at limited sites.The best treatment approach for patients with oligoprogression remains unclear. OBJECTIVE: To determine the ability of stereotactic ablative radiation (SAbR) to extend ongoing systemic therapy in mRCC patients with oligoprogression. DESIGN, SETTING, AND PARTICIPANTS: A single-arm phase II clinical trial was conducted at a university medical center and county hospital, including 20 patients with mRCC on first- to fourth-line systemic therapy with three or fewer sites of progression (including new sites) involving ≤30% of all sites. INTERVENTION: SAbR to oligoprogressing metastases at outset and longitudinally, while radiated sites remain controlled and overall disease oligoprogressive. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary objective was to extend ongoing systemic therapy by >6 mo in >40% of patients. Secondary endpoints included overall survival, toxicity, and patient-reported quality of life. RESULTS AND LIMITATIONS: Twenty patients were enrolled. Upfront and sequential SAbR was administered to a total of 37 sites. The local control rate was 100%. At a median follow-up of 10.4 mo (interquartile range: 5.8-16.4), SAbR extended the duration of the ongoing systemic therapy by >6 mo in 14 patients (70%, 95% confidence interval [CI]: 49.9-90.1). The median time from SAbR to the onset of new systemic therapy or death was 11.1 mo (95% CI: 4.5-19.3). The median duration of SAbR-aided systemic therapy was 24.4 mo (95% CI: 15.3-42.2). Median overall survival was not reached. One patient developed grade 3 gastrointestinal toxicity possibly related to treatment. There was no significant decline in quality of life. Limitations include nonrandomized design and a small patient cohort. CONCLUSIONS: SAbR extended the duration of the ongoing systemic therapy for patients with oligoprogressive mRCC without undermining quality of life. These data support the evaluation of SAbR for oligoprogressive mRCC in a prospective randomized clinical trial. PATIENT SUMMARY: Patients with metastatic kidney cancer on systemic therapy but progressing at limited sites may benefit from focused radiation to progressive sites. Focused radiation was safe and effective, and extended the duration of the ongoing systemic therapy.
引用
- Hannan R, Christensen M, Hammers H, et al. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer. Eur Urol Oncol. 2022. PMID: 34986993. doi:10.1016/j.euo.2021.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。